Select a Region North America

Established Brands

Leverage the Critical Last Few Years

Established/Mature brands require a certain degree of market awareness, disease education and patient interaction with HCPs to understand and identify these products for appropriate use. As these brands’ revenue profiles continue to deteriorate during the course of the pandemic, so do the attention and investment they receive, as well as the already limited brand awareness they have in the healthcare ecosystem. Returning back to “normal revenue levels” is not something that should be assumed will automatically happen once the pandemic is under control.

EVERSANA REIGNITE–  The Next Generation Solution for Life Cycle Management

  • Maximize product value before its loss of exclusivity, and optimize revenue at the late stages of the product life cycle.
  • Increase revenue from an unpromoted product with minimal up-front investment and risk. Inject new life into a mature brand with its own dedicated salesforce, product promotion and HCP engagement.
  • Preserve meaningful value of your brand and patient loyalty.

Purposefully built to act as your engine to reignite revenue  while delivering 1:3 ROI

Imagine not having to divest your established/mature brand portfolio or maintain it “as is.” We have built a foundation you can customize for your product needs. Activate a complete, ready-to-deploy, high-performance model that can shape and execute a path to turn the performance of these brands and generate significant value from a clinical and financial perspective.

We reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE model to slow financial loss and make a positive impact on revenue. With a combined investment, these established brands experienced 1:3 to 3:6 ROI ratios. 

Explore these comprehensive services to support your mature brand strategy, including:


Related Articles

Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products

The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product launches, mature brands are essentially starved of any resources to keep them healthy and vital, even if they are still generating hundreds of millions of dollars in revenue.  Declaring mature brands lifeless well before their time is one of the most common mistakes manufacturers make. While a decline in revenue is inevitable for established brands as loss of exclusivity (LOE) approaches, incremental investments can greatly decrease that decline and yield significant returns. Companies should […]

Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™

Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands out to pasture to invest more in new products, they ignore the significant revenue still to be gained from a loyal base of patients, physician advocates and overall brand awareness. These products tend to be highly promotionally responsive at this point in their lifecycle, and their revenue can be leveraged to replenish investments into new brands that often take years to see prosperity.  By looking at asset optimization across different confounding variables, achieving ample […]

Measuring the Impact of Coordinated Field and Digital Engagement Through Network Influence: An Omnichannel Case Study

In today’s competitive global market, pharmaceutical companies can’t afford to waste time or resources on strategies that don’t generate scripts or fit product and patient needs. Without data-informed, fully integrated campaigns, there’s a missed opportunity to mine deep insights that can inform next steps and accurately pinpoint efforts to doctors and patients who could benefit from additional touch points during the campaign, yielding higher results. Rather than guessing which HCP targets most disproportionately impact script fills, tracking provider networks through data and analytics can provide discrete insight for creating more effective, targeted provider outreach strategies. EVERSANA recently sought answers to this industry challenge by studying which providers are impacting product […]

Moving Forward in Pharma: Reigniting Revenue for Mature Brands

The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in a normal market. These brands have historically provided reliable revenue support, allowing manufacturers to research and develop drugs in new treatment areas. Now, approximately $31.4B of these “recurring” revenue stream brands are facing failure due to COVID-19-related impacts. As COVID-19 cuts into pharma’s bottom line, manufacturers need to begin strategizing how they can address the […]